Why the study?
Does continued use of disease-modifying therapy improve clinical and functional outcomes in patients with rheumatoid arthritis over 10 years?
Population
123 rheumatoid patients followed from the time of prescription of their initial second-line agent
Comparison
Second-line or third-line agents vs Patients not receiving such therapy
Design
Cohort
Follow-up
10 years
Authors
Loading...
Ongoing DMARD use was associated with clinical gains in RA; leaves open causal effects on function and requires randomized confirmation.
Does continued use of disease-modifying therapy improve clinical and functional outcomes in patients with rheumatoid arthritis over 10 years?
Sustained medical and surgical intervention is required over 10 years to minimize disability in rheumatoid arthritis, though continued disease-modifying therapy is associated with improved clinical parameters.
Capell et al. (1991) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: